Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Osteoclast function in Paget's disease and multiple myeloma

G D Roodman1

  • 1Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio, USA.

Bone
|August 1, 1995
PubMed
Summary

Interleukin-6 (IL-6) drives bone resorption in Paget's disease and multiple myeloma by stimulating osteoclast activity. Targeting IL-6 may reduce disease burden in these bone disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth.

Leukemia·2017
Same author

Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.

Leukemia·2016
Same author

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.

Blood cancer journal·2016
Same author

Blocking the ZZ domain of sequestosome1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo.

Leukemia·2015
Same author

Pathogenesis of myeloma bone disease.

Leukemia·2008
Same author

In vivo impact of a 4 bp deletion mutation in the DLX3 gene on bone development.

Developmental biology·2008

Area of Science:

  • Bone biology
  • Oncology
  • Endocrinology

Background:

  • Paget's disease and multiple myeloma feature increased osteoclasts and bone resorption.
  • Osteoclast abnormalities differ between Paget's disease (morphological, viral inclusions) and multiple myeloma (normal).
  • Bone lesions in both conditions stem from local stimulation of osteoclast formation and resorption.

Purpose of the Study:

  • To investigate the role of Interleukin-6 (IL-6) in mediating increased osteoclast activity in Paget's disease and multiple myeloma.
  • To explore IL-6 as a potential autocrine/paracrine factor in these bone diseases.
  • To examine the source and impact of IL-6 in the bone microenvironment of affected patients.

Main Methods:

  • In situ hybridization techniques
  • Bone marrow cultures
  • Cytokine assays (IL-6 levels in marrow plasma and serum)

Main Results:

  • Elevated IL-6 levels are present in serum and marrow plasma of Paget's disease patients.
  • Osteoclasts in Paget's disease produce IL-6 and express IL-6 receptors and mRNA.
  • Increased IL-6 is detected in multiple myeloma patients; IL-6 acts as a myeloma cell growth factor.

Conclusions:

  • IL-6 is implicated as a key mediator of osteoclast overactivity in both Paget's disease and multiple myeloma.
  • IL-6 may function as an autocrine/paracrine factor in the pathogenesis of these diseases.
  • Targeting IL-6 shows therapeutic potential, as anti-IL-6 treatment reduced tumor burden in some multiple myeloma patients.

Related Experiment Videos